Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005
We read with great interest the article by Tohen et al1 “Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression.” We also attended a presentation at the 2003 American Psychiatric Association Annual Meeting2 when the same study was presented and notice rather strangely that the remission rates of the study on both occasions were different even though the study population was the same. At the American Psychiatric Association meeting, the remission rates quoted were placebo, 29.1%; olanzapine, 40.5%; and olanzapine-fluoxetine combination, 56.3%. On the other hand, in the November article, the rates quoted were placebo, 24.5%; olanzapine, 32.8%; and olanzapine-fluoxetine combination, 48.8%. Could the authors please explain the reason(s) for the disparities?
Williams AB, Adetunji BA. Olanzapine and Olanzapine-Fluoxetine Combination Treatment and Bipolar I Depression. Arch Gen Psychiatry. 2005;62(9):1052. doi:10.1001/archpsyc.62.9.1052-a